



Attorney Docket No. 43962.010700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hugo Alfons Geerts et al.

SERIAL NO.: 09/357,349

Group Art Unit: 1647

FILED: July 14, 1999

Examiner: Sharon Turner

FOR: NEUROTROPHIC GROWTH FACTOR

RECEIVED

JUN 27 2003

TECH CENTER 1600/2900

RESPONSE UNDER 37 C.F.R. 1.116

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the United States Patent and Trademark Office Official Action mailed on March 26, 2003, please reconsider the above-identified patent application in light of the following remarks. The remarks advanced should lead to allowance of the application or at the very least reduce the issues on appeal.

Amendment

In the Claims

Please amend claims 8 and 9 as follows:

8. (Three times amended) An isolated human neurotrophic growth factor, designated enovin and having the amino acid sequence known as SEQ ID No. 4, encoded by a nucleic acid molecule encoding said growth factor comprising the amino acid sequence from position 27 to 139 of the amino acid sequence illustrated in Figure 1, known as SEQ ID No. 3.

Do not
enter
ST
9-6-03